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A B S T R A C T
Chemotherapy may result in ovarian atrophy, a depletion of the primordial follicle pool, diminished ovarian
weight, cortical and stromal ﬁbrosis. Imatinib mesylate is an anticancer agent that inhibits competitively several
receptor tyrosine kinases (RTKs). RTKs play important roles in cell metabolism, proliferation, and apoptosis. In
clinic, imatinib mesylate is also known as an anti-ﬁbrotic medicine. In the present study, the impact of imatinib
on the ovarian tissue was investigated by assessing ovarian tissue ﬁbrosis in postnatal rat administered with or
without imatinib for three days. Fibrosis in the ovarian tissue was determined by histology (Picrosirius and
Masson’s trichrome staining) and the protein expression of vimentin and alpha-smooth muscle actin (α-SMA).
Furthermore, mRNA expression of Forkhead box transcription factor O1 and O3 (FOXO1 and FOXO3), which are
markers of cell proliferation was quantiﬁed. A short-term exposure to imatinib showed to increase tissue ﬁbrosis
in ovaries. This was observed by Masson’s trichrome staining. Exposure to imatinib led also to a down-regulation
of vimentin protein expression and up-regulation mRNA expression of FOXO3. This may indicate a role of
FOXO3 in ovarian tissue ﬁbrosis in postnatal rat ovaries.
1. Introduction
The ovarian cortex is composed by connective tissue cells and col-
lagen ﬁbers, which are surrounding the ovarian follicles of diﬀerent
developmental stages. The medulla is described as highly vascularized
stroma usually in the center of the ovary, consisting of connective
tissue, muscle cells, elastic and reticular ﬁbers [1,2]. Development and
maturation of ovarian follicles are related to a communication between
cortex and medulla. Ovarian injury caused by diﬀerent factors, such as
surgery, chemotherapy, radiotherapy, inﬂammation, and immune ab-
normalities can trigger ovarian ﬁbrosis [3–5]. Ovarian tissue ﬁbrosis
can lead to functional decline of the ovary and even premature ovarian
failure [3,5].
Fibrosis is the formation of excess ﬁbrous connective tissue in an
organ or tissue, which attributes to the excessive deposition of extra-
cellular matrix components [6,7]. Diﬀerent factors have been identiﬁed
as important regulators of ﬁbrosis such as; cytokines (IL-13, IL-21, TGF-
β1), chemokines (MCP-1, MIP-1β), angiogenic factors (VEGF), growth
factors (PDGF), peroxisome proliferator-activated receptors (PPARs),
acute phase proteins (SAP), caspases, components of the re-
nin–angiotensin–aldosterone system (ANG II), and Forkhead box O
transcription factors (FOXOs) [5,8–11].
It is shown that some anticancer drugs are able to counteract the
cancer cells without causing ﬁbrosis [12,13]. Imatinib mesylate
(STI517, Glivec®), a tyrosine kinase inhibitor, is known as a targeted
anticancer agent to treat several cancers by blocking receptor tyrosine
kinases to inhibit cell proliferation [14,15]. In clinic, imatinib mesylate
is also used as an anti-ﬁbrotic medicine, for example during treatment
of idiopathic pulmonary ﬁbrosis [13].
The eﬀect of chemotherapeutic agents on ovarian function should
include evaluation of the whole ovary including ovarian follicles, cor-
tical tissue and stromal tissue. In our previous study, we have reported
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that imatinib negatively aﬀects early folliculogenesis in postnatal rat
ovaries [16]. However, eﬀects of imatinib on ovarian ﬁbrosis on post-
natal rats are not known.
In the current study eﬀect of the tyrosine kinase inhibitor, imatinib
on ovarian ﬁbrosis were evaluated after short-term in vivo exposure of
healthy postnatal rats.
2. Materials and methods
2.1. Animals and study design
All experiments were performed on postnatal Sprague Dawley fe-
male rats. The animals (n= 28) were born and maintained under the
standard life conditions for 5 days at the Animal Center of the
Norwegian Institute of Public Health, Oslo, Norway. Ethical permission
for drug treatment was obtained from the Norwegian Institute of Public
Health, Oslo, Norway. From day 2 to 4, the treatment groups (n= 20)
were treated daily by imatinib mesylate (Glivec ®, STI571, Novartis
Pharmaceuticals Corporation, Switzerland) (150mg/kg) dissolved in
water with respect to the rats’ weight (1.2–2.1mg). Both treated and
control animals (n=8) were euthanized on day 5. Bilateral ovar-
iectomy was performed and ovarian samples were collected for histo-
logical, immunoﬂuorescence and mRNA expression analysis at the
Faculty of Veterinary Medicine, Utrecht University, Utrecht, The
Netherlands. The full procedure is described in previous studies
[16,17].
2.2. Tissue ﬁbrosis
2.2.1. Picrosirius red staining
To investigate the structure of ovarian tissue, relative areas of ﬁ-
brosis were evaluated by Picrosirius red staining plus polarization mi-
croscopy in Bouins’ ﬁxed samples [18]. For this, ovaries from 28 rats
(eight from the control group and 20 from the imatinib treated group)
were stained. Picrosirius red is a strong anionic dye that attaches to
collagen ﬁbers, thus ﬁbrotic areas become easily recognizable [18].
When evaluated by light microscopy, collagen is stained red, while
cytoplasm is stained in yellow. Under polarized light microscopy, col-
lagen type I is stained yellow orange birefringence, while collagen type
III is stained green birefringence. In brief, collagen types I and III, were
calculated as a percentage of the area of each image (expressed in
pixels). To avoid counting non-collagen ﬁbers, a color separation on the
original (circularly polarized) images, resolving each into its cyan,
yellow, magenta and black components. Fibrotic area calculation was
performed automatically with the help of the image processing and
analysis software Image J (National Institutes of Health, USA).
2.2.2. Masson's trichrome staining
Masson’s Trichrome stain was performed to determine ﬁbrotic areas
in the ovarian tissue by identifying the relative levels of newly formed
collagen [18,19]. Ovaries (six from each group, i.c. control and imatinib
treated) were ﬁxed in Bouins’ solution and embedded in paraﬃn. The
4 μm deparaﬃnized sections were ﬁrst stained with an acid dye (acid
fuchsin), treated with phosphomolybdic acid and ﬁnally stained with
methyl blue. Old collagen was stained in red, while newly formed
collagen ﬁbers were stained in blue. Newly formed collagen ﬁbers were
stained in blue. Photomicrographs from the Masson’s trichrome–stained
sections were taken with an Olympus BX50 microscope equipped with a
Leica DFC 320 digital camera (magniﬁcation of 100x). As for Picrosirius
red staining, ﬁbrotic area calculation was performed automatically with
the help of the image processing and analysis software Image J (Na-
tional Institutes of Health, USA).
2.3. Immunohistochemical and immunoﬂuorescence labelling
The presence of ﬁbrosis in ovarian tissue can be investigated by the
determination of protein expression of the structural protein vimentin,
as well as alpha-smooth muscle actin (α-SMA) as mesenchymal and
myoﬁbroblast markers [18,20,21]. Ovaries (six from each group, i.c.
control and imatinib treated) ﬁxed in 10% neutral buﬀered formalin
were embedded in paraﬃn, sectioned in 4 μm and deparaﬃnized. The
endogenous peroxidase activity was blocked with 0.3% H2O2 (Merck)
in methanol for 30min at room temperature and rehydrated in a graded
ethanol series to Phosphate Buﬀer Saline (PBS). For antigen retrieval,
the slides were boiled for 10min in 10mM citrate buﬀer (pH 6.0) in a
microwave. The slides were cooled down to room temperature, rinsed
with PBS and blocked with 5% goat serum for 30min at room tem-
perature. The tissue sections were incubated overnight (4 °C) with the
primary antibodies: α-smooth muscle actin (α-SMA, Abcam AB5694,
1:100) or vimentin (Abcam AB24525, 1:200) diluted in PBS containing
1% Bovine Serum Albumin. The negative controls lacking the primary
antibodies were included. Sections were rinsed with PBS followed by
incubation with Alexa-Fluor conjugated secondary antibodies (1:200,
Invitrogen). After washing, the sections were mounted with Prolong
Gold antifade reagent with 4′,6-diamidino-2-phenylindole (DAPI)
(Thermo Fisher Scientiﬁc), immunolocalization was visualized and
images were acquired using the Keyence BZ-9000 microscope (magni-
ﬁcation of 200x). Labelled area was calculated with the help of the
image processing and analysis software Image J (National Institutes of
Health, USA). The relative expression of these proteins was calculated
based on the fold diﬀerence in their expression in imatinib treated
ovaries relative to the control ones.
2.4. Quantitative real time polymerase chain reaction (qRT-PCR)
Total RNA from postnatal rat ovaries (six controls and 11 from
imatinib treated) was extracted by using the Trizol reagent (Invitrogen,
Carlsbad, CA) followed by PureLink™ RNA Mini Kit (Anbion®), ac-
cording to the manufacturer's instructions. The RNA concentration was
estimated by reading the absorbance at 260 nm and was checked for
purity at 280 nm in a spectrophotometer (NanoDrop®2000, Thermo
Fisher Scientiﬁc Inc., Waltham, MA, USA). For each sample, the RNA
concentrations were adjusted to 30 ng/ml and were used to synthesize
cDNA. The reverse transcription was performed with the SuperScript III
RT-PCR kit (Invitrogen). The mixture was incubated at 42 °C for 1 h,
subsequently at 80 °C for 5min, and ﬁnally stored at -20 °C. The ne-
gative control was prepared under the same conditions, but without
addition of the nucleic acid. qRT-PCR was performed using a thermo-
cycler (iQ5, Bio-Rad, Hercules, CA, USA). Primers (Table 1) derived
from the Rattus norvegicus gene were designed using the Pick Primers
designing tool from the National Center for Biotechnology Information
GenBank (NCBI) or based on literature (reference genes; Table 1). A
NCBI basic local alignment search tool (BLAST) ensured the speciﬁcity
of primer sequences. The primers were tested according to the eﬃ-
ciency by qPCR analysis of a dilution series of pooled cDNA at a tem-
perature gradient (55–65 °C) for primer annealing and subsequent
melting curve analysis. The reaction mixture for the qPCR contained
0.5 mg cDNA in sterile water (7.4 ml), 10 ml iQSYBR Green Supermix
(Bio Rad Laboratories Inc.), forward (0.8 ml) and reverse (0.8 ml) pri-
mers (ﬁnal concentration of 0.4 pmol/ml for each primer), according to
the manufacturer's instructions. Data were analyzed using the eﬃciency
corrected Delta-Delta-Ct method (Pfaﬄ MW, 2001). The fold-change
values of the target genes were normalized using the geometric average
of the fold-change values of two reference genes: HPRT and SDHA
(Table 1). The reactions for PCR ampliﬁcation consisted of initial de-
naturation and polymerase activation for 15min at 94 °C, followed by
40 cycles of 15 s at 94 °C, 30 s at 50 °C, 45 s at 72 °C, 15 s at 95 °C and
1min at 60 °C. The method qRT-PCR was performed by using the
thermal cycler CFX96 real-time PCR detection system (Bio-Rad) and
CFX Manager System Software Version 3.0 (Bio Rad). FOXO1 and
FOXO3 were used as the markers for cell proliferation [22,23]. The
fold-change values of the genes encoding FOXO1 and FOXO3 were
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normalized using the geometric average of the fold-change values of the
two reference genes: HPRT and SDHA (Table 1). The relative expression
of FOXO1 and FOXO3 was calculated based on the fold diﬀerence in
their expression in imatinib treated ovaries relative to the control ones.
2.5. Statistical analysis
In all cases, the statistical tests were performed by using software
GraphPad Prism 6. Relative areas of ovarian tissue ﬁbrosis, alpha-SMA,
vimentin, as well as mRNA expression were compared between control
and treated groups with the non-parametric Mann-Whitney test. All
data are presented as mean values ± SEM, the standard errors being
calculated from the variance between samples. P-values ≤ 0.05 in-
dicated statistical signiﬁcance.
3. Results
3.1. Picrosirius and Masson’s trichrome staining
Although Picrosirius red staining showed that the total tissue ﬁ-
brosis increased from 20.1 ± 5.8% in the control group to
39.2 ± 4.1% in the imatinib treated group, this diﬀerence was not
signiﬁcant (P > 0.05). Similarly, the levels of collagen I increased from
0.26 ± 0.15% in the control group to 0.48 ± 0.12% in the imatinib
treated group, while the levels of collagen III increased from
0.23 ± 0.14% in the control group to 0.47 ± 0.13% in the imatinib
treated group, but none of these diﬀerences were signiﬁcant
(P > 0.05) (Fig. 1). However, when the ratio of newly formed col-
lagen: total evaluated tissue section was determined based on Masson’s
trichrome staining, a signiﬁcant (P < 0.0152) increase in newly
formed ﬁbers was observed, where it increased from 0.29 ± 0.11% in
the control group to 1.67 ± 0.66% in the imatinib treated group
(Fig. 1).
3.2. Vimentin and α-SMA protein expression
Imatinib treatment did not aﬀect α-SMA protein expression.
However, a signiﬁcant (P < 0.041) decrease (2.1-fold) was observed
when vimentin expression was determined in imatinib treated ovarian
tissues when compared with control ones (Fig. 2).
3.3. mRNA expression of FOXO1 and FOXO3
The relative mRNA expression levels of FOXO1 and FOXO3 genes
are depicted in Fig. 3. FOXO1 mRNA expression was not aﬀected by
imatinib treatment. However, mRNA expression of FOXO3 increased
(> 5-fold) in imatinib treated ovaries when compared to control.
4. Discussion
Ovarian ﬁbrosis is characterized by excessive proliferation of
ovarian ﬁbroblasts and in addition with the deposition of extracellular
matrix, being one of the main reasons for ovarian dysfunction [3,5,24].
A complex network is involved in the development and progression of
tissue ﬁbrosis. The exact mechanisms involved in ovarian damage by
anticancer treatment are still unclear. However, it is known that
ovarian damage includes follicular apoptosis as well as cortical ﬁbrosis
[3,24].
Imatinib mesylate is known as an anticancer and anti-ﬁbrotic
medicine to treat several cancers by blocking the activity of several
RTKs [13–15]. It is suggested that the eﬀect of imatinib may be based
on its role as an Abelson tyrosine kinase (c-Abl) inhibitor via PI3K/
PTEN/Akt signaling pathways [14,15,25]. There is a controversy in
literature about the eﬀect of imatinib on ovarian function. The initial
reports have shown the protective eﬀect of this drug on chemotherapy-
induced follicle loss in mouse ovary, whereas several other studies have
documented inconsistent results [25–30]. Recently, Bildik et al, showed
molecular evidence for toxicity of imatinib in human ovary [31].
However, anti-ﬁbrotic eﬀect of imatinib on ovarian ﬁbrosis is still
unknown. In the present study, three days imatinib treatment during
early folliculogenesis increased tissue ﬁbrosis in postnatal rat ovaries.
This was concomitantly with up-regulation mRNA expression of FOXO3
together with a down-regulation of vimentin protein expression.
Fibrosis can obliterate the architecture and function of the under-
lying organ or tissue, and it is attributed to an excess in the deposition
of extracellular matrix components, including collagen, in the tissue
[6]. Besides the fact that collagen supports cell structure and archi-
tecture in tissues, it also may act as a signaling molecule, activating
speciﬁc receptors at the cell surface [32].
Among the diﬀerent methods to assess tissue ﬁbrosis in ovarian
tissue, Picrosirius red staining and Masson’s trichome are the most used
[33–35]. Picrosirius red is an anionic dye that can associate with col-
lagen ﬁbers, which are cationic. Picrosirius red is able to bind the total
ﬁbers giving a diﬀerent birefringence to collagen types I and III in tis-
sues with advanced stages of ﬁbrosis [36]. On the other hand, Masson’s
trichome staining is used to detect newly formed collagen [19,33]. In a
previous study with ovarian autografts, it was possible to observe that
the rate of tissue ﬁbrosis detected by Pricosirius Red staining was much
higher than that determined with Masson’s trichome [35]. Further-
more, Gavish et al. used also Masson’s trichome staining to detect early
ﬁbrosis in ovarian grafts [33]. These studies conﬁrm that Masson’s
trichome is more indicated for the assessment of recently formed col-
lagen, as observed in our study. However, none of these methods could
show signiﬁcant changes in collagen I and III in postnatal rat ovaries
after exposure to imatinib.
Studies have identiﬁed collagen as an endogenous ligand for the
discoid in domain receptors 1 and 2 (DDR1 and DDR2) [32,37]. Both
DDR1 and DDR2 are tyrosine kinase receptors [38]. Brieﬂy, collagen
binding to DDR1 induces tyrosine kinase phosphorylation and may
participate in mammary gland formation and breast cancer, whereas
DDR2 is activated only by ﬁbrillary collagens, which act as its en-
dogenous ligand [32,37,38]. Matsumura et al. have indicated DDR2 as
Table 1
Primers used for the mRNA quantiﬁcation of reference genes (stably expressed) and genes of interest.
Genes Accession n° Primer Product size (pb) Source
Reference
HPRT NM_012583.2 F – GCTGAAGATTTGGAAAAGGTG
R – AATCCAGCAGGTCAGCAAAG
157 Hvid et al., 2011
SDHA NM_130428.1 F – AGACGTTTGACAGGGGAATG
R – TCATCAATCCGCACCTTGTA
160 Hvid et al., 2011
Target
FOXO1 NM_001191846.2 F – TGGGTGTCAGGCTAGGAGTT
R – GGCATCTTTGGACTGCTCCT
92 This manuscript
FOXO3 NM_001106395.1 F – AACAGTACCGTGTTCGGACC
R – AGTGTCTGGTTGCCGTAGTG
119 This manuscript
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Fig. 1. Total tissue ﬁbrosis, collagen type I and III in postnatal rat ovarian tissue from control and treated with imatinib, based on Picrosirius red staining (A, B, C)
and ratio of newly formed collagen and total tissue, based on Masson’s trichrome staining (new collagen in blue) (D). Images in panels represent postnatal rat ovarian
tissue from control (E, F, I) and treated imewith imatinib (G, H, J).
Fig. 2. Immunolabelling of α-SMA (A–C) and vimentin (D-F) proteins in ovarian tissue from control group (B, E) and treated with imatinib (C, F). The relaive
expression of these proteins is expressed as fold-change in levels of α-SMA (A) and vimentin (D) in postnatal rat ovaries from control and imatinib treated animals.
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a critical player in ovarian function and regulation, such as anti-apop-
tosis, steroid synthesis, gonadal development, ovulatory cycles and
ovulation [39]. Imatinib is known to inhibit DDRs and regress ﬁbrosis
in mature mammals with cancer [40,41]. In the present study, no sig-
niﬁcant diﬀerences of collagen types I and III between imatinib treated
group and the control groups were observed in postnatal rat ovary
during three days treatment (Fig. 1). However, diﬀerences were ob-
served in the early tissue ﬁbrosis. We may conjecture that the total
amount of collagen may increase over time. Further studies with a
longer treatment duration may show diﬀerent results.
FOXO transcription factors are key regulators of cellular metabo-
lism, proliferation, apoptosis and stress resistance [22]. In ovaries, in-
activity or mutation of these transcription factors have been related to
premature ovarian failure [42]. Transcription factors FOXO1 and
FOXO3 in rodents are highly expressed respectively in granulosa cells
and oocytes at diﬀerent stages of follicle development [43]. They play a
role, not solely on primordial follicle activation, but also on oocyte
maturation, ovulation and luteinization [43,44]. Inactivity or mutation
of these transcription factors has been related to POF [42]. The eﬀect of
imatinib is based on binding to c-Abl kinase and inactivating the PI3K/
Akt/FOXO axis [28,45]. FOXOs have also shown to play a potential role
in tissue ﬁbrosis in other organs e.g. heart, lungs and liver
[11,23,46,47]. As far as we know, the role of FOXOs in ovarian tissue
ﬁbrosis has not been previously described.
In this study, FOXO1 was not aﬀected, while FOXO3 was up-regu-
lated in the imatinib treated postnatal rat ovaries. Activated Akt
phosphorylates a variety of eﬀector molecules including FOXO1, which
then control cell survival and growth [48]. FOXO1 is mostly known as
regulator of cell cycle progression and apoptosis via KL/c-Kit and PI3K
signaling pathways [43]. FOXO1 is important for wound healing by
decreasing ﬁbroblast proliferation [49,50]. Akt phosphorylates and
inactivates FOXO3a by promoting translocation to the cytoplasm,
which promotes proliferation [48]. Studies on the role of FOXO3 on
ﬁbrosis suggest that inactivation of this factor is associated with a de-
creased ﬁbrosis, probably by regulating proliferation and apoptosis
sensitivity [51–53]. FOXO3a deﬁciency protects idiopathic Pulmonary
Fibrosis ﬁbroblasts from type I polymerized collagen matrix-induced
apoptosis via caveolin-1 and Fas [11].
Imatinib inhibit FOXO3 phosphorylation, i.e. its translocation to
cytoplasm of primordial follicles in vitro via PI3K/Akt pathway [45,54].
However, besides phosphorylation, FOXO3 can be also regulated by
acetylation, methylation, glycosylation, redox modulation, and ubi-
quitination, which will determine FOXO3 function [55]. The higher
expression of FOXO3 in imatinib treated postnatal rat ovaries may be
related to ovarian tissue ﬁbrosis in the current study. This is contra-
dictory with the anti-ﬁbrotic eﬀect of imatinib on other type of tissues
compared with ovarian tissue in postnatal rats [51–53,56]. Therefore,
the precise role of FOXO3 in ovarian tissues remains unclear, and it
could be reasonable to postulate that FOXO3 may have another role in
ovarian tissue ﬁbrosis in postnatal rats. In spite of high similarity
among RTKs, it seems there are diﬀerences within their activation,
which could be exploited to obtain kinase selective compounds. These
diﬀerences may depend on species selection and/or some other factors
such as age, type of tissue, dose and duration of treatments.
During ﬁbrogenesis, mutually interacting factors disrupt the balance
between synthesis and degradation of extracellular matrix [5]. In ad-
dition, over-proliferation of ovarian mesenchymal ﬁbroblasts and the
excessive deposition of extracellular matrix may be stimulated [5].
Imatinib inhibits the vascular endothelial growth factor (VEGF), which
in its turn plays a role in ﬁbrosis by upregulating the expression of
collagen and α-SMA [5,57]. Luo et al. found that α-SMA directly reg-
ulates several proﬁbrotic and immune cytokine genes in hepatic stellate
cells [58]. Protein α-SMA is associated with enhanced collagen secre-
tion and, therefore, represents a critical transition in ﬁbrogenesis [59].
(Challa and Stefanovic 2011, Hinz 2016) In the present study, imatinib
did not aﬀect the expression of α-SMA. This shows that ﬁbrosis may
occur via a diﬀerent pathway. On the other hand, vimentin expression
was reduced signiﬁcantly in imatinib treated postnatal rat ovaries. Vi-
mentin ﬁlaments are important in the development of tissue ﬁbrosis by
stabilizing the collagen I and promoting ﬁbroblasts migration [60,61].
Disruption of vimentin reduces synthesis of type I collagen [60]. From a
therapeutic point of view, the increased collagen expression has a
central role in the development of tissue ﬁbrosis [60]. Vimentin ﬁla-
ments are known as a target for anti-ﬁbrotic therapy where imatinib
treatment prevents tissue ﬁbrosis by reducing the vimentin expression
[60,62]. As expected, the present study showed a decrease in vimentin
expression caused by imatinib administration. However, without
avoiding ovarian tissue ﬁbrosis. Vimentin is involved in sequestering
and degradation of FOXO3 [61]. Hence, this ﬁnding shows that ﬁbrosis
does not only follow a vimentin-dependent pathway in postnatal rat
ovaries and other targets than collagen type I should be considered.
The present study suggests that anti-ﬁbrotic eﬀects of imatinib in
ovaries may be age-dependent. Observation is in line with previous
reports where imatinib has shown to interfere with physiological signal
cascades and this modulation has varied signiﬁcantly with age and
maturational status [17,63]. However, further studies are needed to
evaluate diﬀerences in mechanism of ovarian ﬁbrosis at diﬀerent ma-
turational stages with a longer treatment duration. Consequently, be-
fore introducing imatinib as an anti-ﬁbrotic drug we need more in-
formation about the complicated mechanism action of this drug in
diﬀerent tissues and its possible age-dependent adverse eﬀects on
ovarian stroma.
5. Conclusion
In conclusion, increased tissue ﬁbrosis in postnatal rat ovaries
treated with imatinib is probably related to a down-regulation of vi-
mentin protein expression and up-regulation mRNA expression of
FOXO3. More investigation of other related up/downstream proteins
involved in ﬁbrosis in postnatal rat ovaries might strengthen this ob-
servation.
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Fig. 3. The fold-change in mRNA expression levels of FOXO1 (A) and FOXO3
(B) genes in postnatal rat ovaries from control and imatinib treated animals.
B. Asadi-Azarbaijani, et al. Reproductive Biology xxx (xxxx) xxx–xxx
5
Transparency document
The Transparency document associated with this article can be
found in the online version.
Acknowledgment
We would like to thank Trude Olsen at Norwegian Institute of Public
Health, Oslo, Norway for her help at animal house.
References
[1] Bochner F, et al. A novel intravital imaging window for longitudinal microscopy of
the mouse ovary. Sci Rep 2015;5:12446.
[2] Kuehnel W. Color atlas of cytology, histology, and microscopic anatomy. 4. edition,
revised and enlarged. ed. thieme ﬂexibook ix. Stuttgart/New York: Thieme; 2003. p.
534s.
[3] Meirow D, et al. Cortical ﬁbrosis and blood-vessels damage in human ovaries ex-
posed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod
2007;22(6):1626–33.
[4] Meirow D, et al. Searching for evidence of disease and malignant cell contamination
in ovarian tissue stored from hematologic cancer patients. Hum Reprod
2008;23(5):1007–13.
[5] Zhou F, Shi LB, Zhang SY. Ovarian ﬁbrosis: A phenomenon of concern. Chin Med J
(Engl) 2017;130(3):365–71.
[6] Wynn TA. Cellular and molecular mechanisms of ﬁbrosis. J Pathol
2008;214(2):199–210.
[7] Revelon G, et al. Focal ﬁbrosis of the breast: imaging characteristics and histo-
pathologic correlation. Radiology 2000;216(1):255–9.
[8] Wynn TA. Common and unique mechanisms regulate ﬁbrosis in various ﬁ-
broproliferative diseases. J Clin Invest 2007;117(3):524–9.
[9] Tomasek JJ, et al. Myoﬁbroblasts and mechano-regulation of connective tissue re-
modelling. Nat Rev Mol Cell Biol 2002;3(5):349–63.
[10] Friedman SL. mechanisms of disease: mechanisms of hepatic ﬁbrosis and ther-
apeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004;1(2):98–105.
[11] Nho RS, et al. Pathological alteration of FoxO3a activity promotes idiopathic pul-
monary ﬁbrosis ﬁbroblast proliferation on type i collagen matrix. Am J Pathol
2011;179(5):2420–30.
[12] Torres VE, Leof EB. Fibrosis, regeneration, and aging: playing chess with evolution.
J Am Soc Nephrol 2011;22(8):1393–6.
[13] Beyer C, Distler JH. Tyrosine kinase signaling in ﬁbrotic disorders: translation of
basic research to human disease. Biochim Biophys Acta 2013;1832(7):897–904.
[14] Buchdunger E, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro
signal transduction mediated by c-kit and platelet-derived growth factor receptors.
J Pharmacol Exp Ther 2000;295(1):139–45.
[15] Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a ther-
apeutic agent for chronic myeloid leukemia. Blood 2005;105(7):2640–53.
[16] Asadi-Azarbaijani B, et al. Developmental eﬀects of imatinib mesylate on follicle
assembly and early activation of primordial follicle pool in postnatal rat ovary.
Reprod Biol 2017;17(1):25–33.
[17] Nurmio M, et al. Receptor tyrosine kinase inhibition causes simultaneous bone loss
and excess bone formation within growing bone in rats. Toxicol Appl Pharmacol
2011;254(3):267–79.
[18] Liu X, et al. Corroborating evidence for platelet-induced epithelial-mesenchymal
transition and ﬁbroblast-to-myoﬁbroblast transdiﬀerentiation in the development
of adenomyosis. Hum Reprod 2016;31(4):734–49.
[19] Guo X, et al. Grafting of mesenchymal stem cell-seeded small intestinal submucosa
to repair the deep partial-thickness burns. Connect Tissue Res 2016;57(5):388–97.
[20] Huang Y, et al. Enhanced eﬃcacy and speciﬁcity of epithelial ovarian carcino-
genesis by embedding a DMBA-coated cloth strip in the ovary of rat. J Ovarian Res
2012;5(1):21.
[21] Chen CM, Chang JL, Behringer RR. Tumor formation in p53 mutant ovaries
transplanted into wild-type female hosts. Oncogene 2004;23(46):7722–5.
[22] Martins R, Lithgow GJ, Link W. Long live FOXO: unraveling the role of FOXO
proteins in aging and longevity. Aging Cell 2016;15(2):196–207.
[23] Xin Z, et al. FOXO1/3: potential suppressors of ﬁbrosis. Ageing Res Rev
2018;41:42–52.
[24] Meirow D, et al. Toxicity of chemotherapy and radiation on female reproduction.
Clin Obstet Gynecol 2010;53(4):727–39.
[25] Gonﬂoni S, et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes
from chemotherapy-induced death. Nat Med 2009;15(10):1179–85.
[26] Kerr JB, et al. Cisplatin-induced primordial follicle oocyte killing and loss of fertility
are not prevented by imatinib. Nat Med 2012;18(8):1170–2.
[27] Carlsson IB, et al. Kit ligand and c-Kit are expressed during early human ovarian
follicular development and their interaction is required for the survival of follicles
in long-term culture. Reproduction 2006;131(4):641–9.
[28] Kim SY, et al. Rescue of platinum-damaged oocytes from programmed cell death
through inactivation of the p53 family signaling network. Cell Death Diﬀer
2013;20(8):987–97.
[29] Morgan S, et al. Cisplatin and doxorubicin induce distinct mechanisms of ovarian
follicle loss; imatinib provides selective protection only against cisplatin. PLoS One
2013;8(7):e70117.
[30] Tuppi M, et al. Oocyte DNA damage quality control requires consecutive interplay
of CHK2 and CK1 to activate p63. Nat Struct Mol Biol 2018;25(3):261–9.
[31] Bildik G, et al. C-Abl is not activated in DNA damage-induced and Tap63-mediated
oocyte apoptosis in human ovary. Cell Death Dis 2018;9(10):943.
[32] Leitinger B, Hohenester E. Mammalian collagen receptors. Matrix Biol
2007;26(3):146–55.
[33] Gavish Z, et al. Follicle activation and’ burn-out’ contribute to post-transplantation
follicle loss in ovarian tissue grafts: the eﬀect of graft thickness. Hum Reprod
2015;30(4):1003.
[34] Briley SM, et al. Reproductive age-associated ﬁbrosis in the stroma of the mam-
malian ovary. Reproduction 2016;152(3):245–60.
[35] Scalercio SR, et al. Trolox enhances follicular survival after ovarian tissue autograft
in squirrel monkey (Saimiri collinsi). Reprod Fertil Dev 2015.
[36] Lattouf R, et al. Picrosirius red staining: a useful tool to appraise collagen networks
in normal and pathological tissues. J Histochem Cytochem 2014;62(10):751–8.
[37] Vogel W. Discoidin domain receptors: structural relations and functional implica-
tions. FASEB J 1999;13(Suppl):S77–82.
[38] Vogel W, et al. The discoidin domain receptor tyrosine kinases are activated by
collagen. Mol.Cell 1997;1(1):13–23.
[39] Matsumura H, et al. Transcriptome analysis reveals an unexpected role of a collagen
tyrosine kinase receptor gene, Ddr2, as a regulator of ovarian function. Physiol
Genomics 2009;39(2):120–9.
[40] Manley PW, et al. Structural resemblances and comparisons of the relative phar-
macological properties of imatinib and nilotinib. Bioorg Med Chem
2010;18(19):6977–86.
[41] Day E, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 ac-
tivation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008;599(1-
3):44–53.
[42] Watkins WJ, et al. Mutational screening of FOXO3A and FOXO1A in women with
premature ovarian failure. Fertil Steril 2006;86(5):1518–21.
[43] Kuscu N, Celik-Ozenci C. FOXO1, FOXO3, AND FOXO4 are diﬀerently expressed
during mouse oocyte maturation and preimplantation embryo development. Gene
Expr Patterns 2015;18(1-2):16–20.
[44] Pisarska MD, et al. Expression of forkhead transcription factors in human granulosa
cells. Fertil Steril 2009;91(4 Suppl):1392–4.
[45] Ezzati MM, et al. Regulation of FOXO3 subcellular localization by kit ligand in the
neonatal mouse ovary. J Assist Reprod Genet 2015;32(12):1741–7.
[46] Norambuena-Soto I, et al. Transforming growth factor-beta and Forkhead box O
transcription factors as cardiac ﬁbroblast regulators. Biosci Trends
2017;11(2):154–62.
[47] Adachi M, et al. The forkhead transcription factor FoxO1 regulates proliferation and
transdiﬀerentiation of hepatic stellate cells. Gastroenterology
2007;132(4):1434–46.
[48] Makker A, Goel MM, Mahdi AA. PI3K/PTEN/Akt and TSC/mTOR signaling path-
ways, ovarian dysfunction, and infertility: an update. J Mol Endocrinol
2014;53(3):R103–18.
[49] Alikhani M, Alikhani Z, Graves DT. FOXO1 functions as a master switch that reg-
ulates gene expression necessary for tumor necrosis factor-induced ﬁbroblast
apoptosis. J Biol Chem 2005;280(13):12096–102.
[50] Wang XW, Yu Y, Gu L. Dehydroabietic acid reverses TNF-alpha-induced the acti-
vation of FOXO1 and suppression of TGF-beta1/Smad signaling in human adult
dermal ﬁbroblasts. Int J Clin Exp Pathol 2014;7(12):8616–26.
[51] Lin CH, et al. Resveratrol enhanced FOXO3 phosphorylation via synergetic acti-
vation of SIRT1 and PI3K/Akt signaling to improve the eﬀects of exercise in elderly
rat hearts. Age (Dordr) 2014;36(5):9705.
[52] Pramod S, Shivakumar K. Mechanisms in cardiac ﬁbroblast growth: an obligate role
for Skp2 and FOXO3a in ERK1/2 MAPK-dependent regulation of p27kip1. Am J
Physiol Heart Circ Physiol 2014;306(6):H844–55.
[53] Pei XM, et al. Protective eﬀects of desacyl ghrelin on diabetic cardiomyopathy. Acta
Diabetol 2015;52(2):293–306.
[54] Naka K, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in
chronic myeloid leukaemia. Nature 2010;463(7281):676–80.
[55] Liang R, et al. Evidence for AKT-independent regulation of FOXO1 and FOXO3 in
haematopoietic stem and progenitor cells. Cell Cycle 2016;15(6):861–7.
[56] Vittal R, et al. Eﬀects of the protein kinase inhibitor, imatinib mesylate, on epi-
thelial/mesenchymal phenotypes: implications for treatment of ﬁbrotic diseases. J
Pharmacol Exp Ther 2007;321(1):35–44.
[57] Raimondi C, et al. Imatinib inhibits VEGF-independent angiogenesis by targeting
neuropilin 1-dependent ABL1 activation in endothelial cells. J Exp Med
2014;211(6):1167–83.
[58] Luo J, et al. Vascular endothelial growth factor promotes the activation of hepatic
stellate cells in chronic schistosomiasis. Immunol Cell Biol 2017;95(4):399–407.
[59] Hinz B. Myoﬁbroblasts. Exp Eye Res 2016;142:56–70.
[60] Challa AA, Stefanovic B. A novel role of vimentin ﬁlaments: binding and stabili-
zation of collagen mRNAs. Mol Cell Biol 2011;31(18):3773–89.
[61] Kidd ME, Shumaker DK, Ridge KM. The role of vimentin intermediate ﬁlaments in
the progression of lung cancer. Am J Respir Cell Mol Biol 2014;50(1):1–6.
[62] Sancho M, et al. Proliferation of interstitial cells in the cyclophosphamide-induced
cystitis and the preventive eﬀect of imatinib. Biomed Res Int 2017;2017:3457093.
[63] Nurmio M, et al. Adult reproductive functions after early postnatal inhibition by
imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis.
Reprod Toxicol 2008;25(4):442–6.
B. Asadi-Azarbaijani, et al. Reproductive Biology xxx (xxxx) xxx–xxx
6
